Skip to main content
SpringerLink
Log in

Surgical Approach in the Treatment of Neuroendocrine Tumours

  • Chapter
Neuroendocrine Tumours

  • 1639 Accesses

Abstract

Gastroentero-pancreatic neuroendocrine tumours (GEP)-NETs have had rising incidence during recent decades, due to improved detection by multidimensional imaging and endoscopy and increased awareness of histological features. A majority of NETs have malignant properties, but often have slow and indolent progression, except a minority group with poor differentiation and aggressive behaviour. Foregut or gastric NETs have variable disease presentation and different, type specific requirements of treatment. The most common gastric NETs occur secondary to chronic atrophic gastritis (CAG), with considerably more benign features than non-CAG-related gastric NETs. Metastatic midgut or small intestinal NETs (Si-NETs) have been over-represented at referral centres, as the common cause of the carcinoid syndrome, which has required combined oncologic and surgical treatment. The Si-NETs have early spread to locoregional lymph nodes, the root of the mesentery and the liver, but may with appropriate surgery and somatostatin analogue treatment expect long survival. Hindgut or colorectal NETs are not associated with the carcinoid syndrome; the vast majority present as incidentally discovered small polyps, which can be safely removed by endoscopy, whereas larger and deeper invasive lesions often require extensive surgery combined with other treatment. Surgery is the only potentially curative therapy for localised NETs, but may often be crucially important also with advanced disease. Appropriate surgery can be a necessary prerequisite and improve results of other treatments. A multidisciplinary approach, with involvement of oncologists, surgeons, radiologists and pathologists, has proved important for recent progress in the management of NETs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rindi G, Kloppel G, Ahlman H et al (2006) TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401

    PubMed Central  CAS  PubMed  Google Scholar 

  2. Rindi G, Kloppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762

    CAS  PubMed  Google Scholar 

  3. Öberg K, Åkerström G, Rindi G, Jelic S (2010) Neuroendocrine gastroenteropancreatic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v223–v227

    PubMed  Google Scholar 

  4. Bosman FT, World Health Organization, International Agency for Research on Cancer (2010) WHO classification of tumours of the digestive system, 4th edn. International Agency for Research on Cancer, Lyon, p 417

    Google Scholar 

  5. Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumors. A review of nomenclature, grading and staging systems. Pancreas 39:707–712

    PubMed  Google Scholar 

  6. Scarpa A, Mantovani W, Capelli P, Beghelli S, Bonisegna L, Bettini R et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23(6):824–833

    CAS  PubMed  Google Scholar 

  7. Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C, Delle Fave G, Fischer L, Fusai G, de Herder WW, Jann H, Komminoth P, de Krijger RR, La Rosa S, Luong TV, Pape U, Perren A, Ruszniewski P, Scarpa A, Schmitt A, Solcia E, Wiedenmann B (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104(10):764–777. doi:10.1093/jnci/djs20836

    CAS  PubMed  Google Scholar 

  8. Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T (2013) A comparison of Ki67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer 108(9):1838–1845

    PubMed Central  CAS  PubMed  Google Scholar 

  9. Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A (2014) Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. World J Surg. doi:10.1007/s00268-014-2451-0

    Google Scholar 

  10. Frilling A, Åkerström G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin I (2012) Neuroendocrine tumor disease – an evolving landscape. Endocr Relat Cancer 19:R163–R185

    CAS  PubMed  Google Scholar 

  11. Elvin A (1993) Therapy evaluation and diagnostic accuracy in neuroendocrine tumours: assessment of radiological methods. Acta Radiol Suppl 390:1–25

    CAS  PubMed  Google Scholar 

  12. Akerstrom G, Hellman P, Hessman O (2009) Gastrointestinal carcinoids. In: Lennard T (ed) Endocrine surgery, 4th edn. Saunders Elsevier, London, pp 147–176

    Google Scholar 

  13. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40:1–18

    PubMed  Google Scholar 

  14. Granberg D, Wilander E, Stridsberg M et al (1998) Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 43:223–228

    PubMed Central  CAS  PubMed  Google Scholar 

  15. Jensen EH, Kvols L, McLoughlin JM et al (2007) Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol 14:780–785

    PubMed  Google Scholar 

  16. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL, de Vries EG (2008) Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 26:1489–1495. doi:10.1200/JCO.2007.15.1126

    PubMed  Google Scholar 

  17. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, Schilling T, Haufe S, Herrmann T, Haberkorn U (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617–1626. doi:10.1007/s00259-007-0450-1

    CAS  PubMed  Google Scholar 

  18. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP (2010) Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37:67–77. doi:10.1007/s00259-009-1205-y

    CAS  PubMed  Google Scholar 

  19. Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE (2010) The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 252:850–856. doi:10.1097/SLA.0b013e3181fd37e8

    PubMed  Google Scholar 

  20. Binderup T, Knigge U, Loft A et al (2010) Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 51:704–712

    PubMed  Google Scholar 

  21. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD (2005) Current status of gastrointestinal carcinoids. Gastroenterology 128:1717–1751

    PubMed  Google Scholar 

  22. O’Toole D, Delle Fave G, Jensen RT, Delle Fave G, Jensen RT (2012) Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol 26(6):719–735. doi:10.1016/j.bpg.2013.01.002

    PubMed  Google Scholar 

  23. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L (2005) Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242:64–73. doi:10.1097/01.sla.0000167862.52309.7d

    PubMed Central  PubMed  Google Scholar 

  24. Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H et al (2006) Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 84:158–164. doi:10.1159/000098007

    CAS  PubMed  Google Scholar 

  25. Hopper AD, Bourke MJ, Hourigan LF, Tran K, Moss A, Swan MP (2009) En-bloc resection of multiple type 1 gastric carcinoid tumors by endoscopic multi-band mucosectomy. J Gastroenterol Hepatol 24:1516–1521. doi:10.1111/j.1440-1746.2009.05909.x

    PubMed  Google Scholar 

  26. Burkitt MD, Pritchard DM (2006) Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 24:1305–1320. doi:10.1111/j.1365-2036.2006.03130.x

    CAS  PubMed  Google Scholar 

  27. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL (2004) Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 39:621–628. doi:10.1080/00365520410005225

    CAS  PubMed  Google Scholar 

  28. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P (2008) Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 15:337–342. doi:10.1677/ERC-07-0251

    CAS  PubMed  Google Scholar 

  29. Jianu CS, Fossmark R, Syversen U, Hauso O, Fykse V, Waldum HL (2011) Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol 46:456–463. doi:10.3109/00365521.2010.539255

    PubMed  Google Scholar 

  30. Richards ML, Gauger P, Thompson NW, Giordano TJ (2004) Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger–Ellison syndrome after surgical excision of all gastrinomas. World J Surg 28:652–658. doi:10.1007/s00268-004-7345-0

    PubMed  Google Scholar 

  31. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L (2000) Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 343:551–554. doi:10.1056/NEJM200008243430805

    CAS  PubMed  Google Scholar 

  32. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W, Metz DC (2000) Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger–Ellison syndrome. Gastroenterology 118:696–704. doi:10.1016/S0016-5085(00)70139-9

    CAS  PubMed  Google Scholar 

  33. Kaehler G, Grobholz R, Langner C, Suchan K, Post S (2006) A new technique of endoscopic full-thickness resection using a flexible stapler. Endoscopy 38:86–89. doi:10.1055/s-2005-921181

    CAS  PubMed  Google Scholar 

  34. Jensen RT, Rindi G, Arnold R, Lopes JM, Bechstein WO et al (2006) Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology 84:165–172

    CAS  PubMed  Google Scholar 

  35. Wheeler MH, Curley IR, Williams ED (1986) The association of neurofibromatosis pheochromocytoma, and somatostatin-rich duodenal carcinoid tumor. Surgery 100:1163–1169

    CAS  PubMed  Google Scholar 

  36. Burke AP, Sobin LH, Federspiel BH et al (1990) Carcinoid tumors of the duodenum. A clinicopathologic study of 99 cases. Arch Pathol Lab Med 114:700–704

    CAS  PubMed  Google Scholar 

  37. Zyromski NJ, Kendrick ML, Nagomey DM et al (2001) Duodenal carcinoid tumors: how aggressive should we be? J Gastrointest Surg 5:588–593

    CAS  PubMed  Google Scholar 

  38. Wilson RW, Gal AA, Cohen C et al (1991) Serotonin immunoreactivity in pancreatic endocrine neoplasms (carcinoid tumors). Mod Pathol 4:727–732

    CAS  PubMed  Google Scholar 

  39. Berge T, Linell F (1976) Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Microbiol Scand 84(4):322–330

    CAS  Google Scholar 

  40. Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B et al (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors- well-differentiated jejunal-ileal tumor/carcinoma. Neuroenedocrinology 87:8–19

    CAS  Google Scholar 

  41. Strosberg J (2012) Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol 26:755–773

    CAS  PubMed  Google Scholar 

  42. Norlen O, Stalberg P, Oberg K, Eriksson J, Hedberg J, Hessman O, Janson ET, Hellman P, Åkerström G (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 36:1419–1431

    PubMed  Google Scholar 

  43. Makridis C, Öberg K, Juhlin C, Johansson H, Lörelius LE, Åkerström G (1990) Surgical treatment of midgut carcinoid tumors. World J Surg 14:377–385

    CAS  PubMed  Google Scholar 

  44. Guo Z, Li Q, Wilander E et al (2000) Clonality analysis of multifocal carcinoid tumours of the small intestine by X-chromosome inactivation analysis. J Pathol 190:76–79

    CAS  PubMed  Google Scholar 

  45. Åkerström G, Hellman P, Öhrvall U (2001) Midgut and hindgut carcinoid tumors. In: Doherty GM, Skogseid B (eds) Surgical endocrinology. Lippincott Williams & Wilkins, Philadelphia, pp 447–459

    Google Scholar 

  46. Funa K, Papanicolaou V, Juhlin C, Rastad J, Åkerström G, Heldin C, Oberg K (1990) Expression of platelet-derived growth factor β-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 50:748–753

    CAS  PubMed  Google Scholar 

  47. Kidd M, Modlin IM (2011) Small intestinal neuroendocrine cell pathobiology: ‘carcinoid’ tumors. Curr Opin Oncol 23(1):45–52. doi:10.1097/CCO.0b013e328340d006

    PubMed  Google Scholar 

  48. Makridis C, Ekbom A, Bring J et al (1997) Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery 122:1075–1082

    CAS  PubMed  Google Scholar 

  49. Öhrvall U, Eriksson B, Juhlin C et al (2000) Method of dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 24:1402–1408

    PubMed  Google Scholar 

  50. Eckhauser FE, Argenta LC, Strodel WE et al (1981) Mesenteric angiopathy, intestinal gangrene and midgut carcinoids. Surgery 90:720–728

    CAS  PubMed  Google Scholar 

  51. Knowlessar OD, Law DH, Sleisinger MH (1959) Malabsorption syndrome associated with metastatic carcinoid tumor. Am J Med 27:673–677

    Google Scholar 

  52. Vinik AI, McLeod MK, Fig LM, Shapiro B, Lloyd RV, Cho K (1989) Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 18(4):865–896. Review

    CAS  PubMed  Google Scholar 

  53. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959

    PubMed  Google Scholar 

  54. Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 89(4):471–476

    CAS  PubMed  Google Scholar 

  55. Jacobs C (2009) Neuroendocrine tumors a rare finding: part I. Clin J Oncol Nurs 13:21–23. doi:10.1188/09.CJON.21-23

    PubMed  Google Scholar 

  56. Mooney E (1985) The flushing patient. Int J Dermatol 24:549–554

    CAS  PubMed  Google Scholar 

  57. Matuchansky C, Launay JM (1995) Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites. Gastroenterology 108:743–751

    CAS  PubMed  Google Scholar 

  58. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK (1993) Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 87:1188–1196

    CAS  PubMed  Google Scholar 

  59. Lundin L, Hansson HE, Landelius J et al (1990) Surgical treatment of carcinoid heart disease. J Thorac Cardiovasc Surg 100:552–561

    CAS  PubMed  Google Scholar 

  60. Westberg G, Wängberg B, Ahlman H et al (2001) Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 88:865–872

    CAS  PubMed  Google Scholar 

  61. Öberg K (1998) Carcinoid tumors: current concepts in diagnosis and treatment. Oncologist 3:339–345

    PubMed  Google Scholar 

  62. Öhrlefors H, Sundin A, Ahlström H et al (1998) Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors. J Clin Oncol 16:2534–2541

    Google Scholar 

  63. Makridis C, Rastad J, Öberg K et al (1996) Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 20:900–907

    CAS  PubMed  Google Scholar 

  64. Hellman P, Lundström T, Öhrvall U et al (2002) Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26:991–997

    PubMed  Google Scholar 

  65. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663. doi:10.1200/JCO.2009.22.8510

    CAS  PubMed  Google Scholar 

  66. Kianmanesh R, Ruszniewski P, Rindi G, Kwekkeboom D, Pape UF, Kulke M, Sevilla Garcia I, Scoazec JY, Nilsson O, Fazio N, Lesurtel M, Chen YJ, Eriksson B, Cioppi F, O'Toole D (2010) ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology 91(4):333–340. doi:10.1159/000286700

    CAS  PubMed  Google Scholar 

  67. Elias D, Sideris L, Liberale G, Ducreux M, Malka D, Lasser P, Duvillard P, Baudin E (2005) Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery 137:411–416

    PubMed  Google Scholar 

  68. Frilling A, Modlin IM, Kidd M et al (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15(1):e8–e21. doi:10.1016/S1470-2045(13)70362-0

    PubMed  Google Scholar 

  69. Jann H, Roll S, Couvelard A et al (2011) Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117:3332–3341

    PubMed  Google Scholar 

  70. Landerholm K, Zar N, Andersson RE, Falkmer SE, Jarhult J (2011) Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 98:1617–1624

    CAS  PubMed  Google Scholar 

  71. Knigge U, Hansen CP (2012) Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol 26(6):819–831

    PubMed  Google Scholar 

  72. Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kvekkebom DJ et al (2008) Consensus guidelines for the management of liver metastases from (digestive) neuroendocrine tumors: foregut, midgut, hindgut and unknown primary. Neuroendocrinology 87:47–62

    PubMed  Google Scholar 

  73. Mazzaferro V, Pulvirenti A, Coppa J (2007) Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol 47:460–466. doi:10.1016/j.jhep.2007.07.004

    PubMed  Google Scholar 

  74. Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Levy P, Vilgrain V, Ruszniewski P, Belghiti J (2008) Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 247:659–665. doi:10.1097/SLA.0b013e31816a7061

    PubMed  Google Scholar 

  75. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE (2009) Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 96(2):175–184

    CAS  PubMed  Google Scholar 

  76. Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, Vullierme MP, Couvelard A, Belghiti J, Ruszniewski P et al (2009) Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer 16:977–990. doi:10.1677/ERC-08-0247

    CAS  PubMed  Google Scholar 

  77. Elias D, Lefevre JH, Duvillard P, Goere D, Dromain C, Dumont F et al (2010) Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg 251(2):307–310

    PubMed  Google Scholar 

  78. Norlen O, Stalberg P, Zedenius J, Hellman P (2013) Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours. Br J Surg 100(11):1505–1514

    CAS  PubMed  Google Scholar 

  79. Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R (2012) Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am J Clin Oncol 35(4):393–398

    PubMed  Google Scholar 

  80. Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A (2012) Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist 17(5):725–731

    PubMed Central  PubMed  Google Scholar 

  81. Oberg KE (2012) The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol 24(4):282–293

    CAS  Google Scholar 

  82. van Essen M, Krenning EP, Bakker WH, de Herder WW, van Aken MO, Kwekkeboom DJ (2007) Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 34(8):1219–1227

    PubMed  Google Scholar 

  83. Caplin M, Ruszniewski P, Pavel M, Cwikla J, Phan A, Raderer M et al (2013) A randomized, double-blind, placebo-Controlled study of Lanreotide Antiproliferative Response in patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET). The European Cancer Congress, Amsterdam

    Google Scholar 

  84. Garske U (2012) 177Lu-DOTA-octreotate radionuclide therapy of neuroendocrine tumours dosimetry-based therapy planning and outcome. Dissertation, Uppsala University

    Google Scholar 

  85. Krausch M, Raffel A, Anlauf M, Schott M, Lehwald N, Krieg A et al (2014) “Cherry picking”, a multiple non-anatomic liver resection technique, as a promising option for diffuse liver metastases in patients with neuroendocrine tumours. World J Surg 38(2):392–401

    PubMed  Google Scholar 

  86. Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B et al (2008) Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 32(5):930–938

    PubMed  Google Scholar 

  87. Ahlman H, Westberg G, Wangberg B, Nilsson O, Tylen U, Schersten T et al (1996) Treatment of liver metastases of carcinoid tumors. World J Surg 20(2):196–202

    CAS  PubMed  Google Scholar 

  88. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108(6):1091–1096

    CAS  PubMed  Google Scholar 

  89. Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT (2003) Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 138(8):859–866

    PubMed  Google Scholar 

  90. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5):776–783; discussion 783–785

    PubMed Central  PubMed  Google Scholar 

  91. Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E (2010) Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 148(6):1288–1293; discussion 1293

    PubMed  Google Scholar 

  92. Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A (2002) Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26(8):1052–1056

    PubMed  Google Scholar 

  93. Groeschl RT, Pilgrim CH, Hanna EM, Simo KA, Swan RZ, Sindram D et al (2013) Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 259(6):1195–1200. PMID:24096760

    Google Scholar 

  94. Strosberg JR, Choi J, Cantor AB, Kvols LK (2006) Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 13(1):72–78

    PubMed  Google Scholar 

  95. Schell SR, Camp ER, Caridi JG, Hawkins IF Jr (2002) Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6(5):664–670

    PubMed  Google Scholar 

  96. Lewis MA, Hubbard J (2011) Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol. doi:10.4061/2011/452343

    PubMed Central  PubMed  Google Scholar 

  97. Granberg D, Eriksson LG, Welin S, Kindmark H, Janson ET, Skogseid B et al (2007) Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors. Acta Radiol 48(2):180–185

    CAS  PubMed  Google Scholar 

  98. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB et al (2006) Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transplant: Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 12(3):448–456

    Google Scholar 

  99. Pascher A, Klupp J, Neuhaus P (2006) Endocrine tumours of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 19(4):637–648

    Google Scholar 

  100. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S et al (2007) Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transplant: Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 13(3):327–333

    Google Scholar 

  101. Lehnert T (1998) Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 66(10):1307–1312

    CAS  PubMed  Google Scholar 

  102. Norlen O, Daskalakis K, Oberg K, Akerstrom G, Stalberg P, Hellman P (2013) Indication for liver transplantation in young patients with small intestinal NETs is rare? World J Surg 38(3):742–747

    Google Scholar 

  103. Akerström G, Falconi M, Kianmanesh R et al (2009) ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology 90:203–208

    PubMed  Google Scholar 

  104. Strosberg J, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK (2013) Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 31(4):420–425. doi:10.1200/JCO.2012.44.5924

    PubMed  Google Scholar 

  105. Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P et al (2011) Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer 18(1):51–59

    CAS  PubMed  Google Scholar 

  106. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072

    PubMed  Google Scholar 

  107. In't Hof KH, van der Wal HC, Kazemier G, Lange JF (2008) Carcinoid tumour of the appendix: an analysis of 1,485 consecutive emergency appendectomies. J Gastrointest Surg 12(8):1436–1438

    PubMed Central  PubMed  Google Scholar 

  108. Goede AC, Caplin ME, Winslet MC (2003) Carcinoid tumour of the appendix. Br J Surg 90(11):1317–1322

    CAS  PubMed  Google Scholar 

  109. Plockinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E et al (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology 87(1):20–30

    PubMed  Google Scholar 

  110. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F et al (2012) ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95(2):135–156

    CAS  PubMed  Google Scholar 

  111. Cashin P, Nygren P, Hellman P, Granberg D, Andreasson H, Mahteme H (2011) Appendiceal adenocarcinoids with peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy: a retrospective study of in vitro drug sensitivity and survival. Clin Colorectal Cancer 10(2):108–112

    CAS  PubMed  Google Scholar 

  112. O'Donnell ME, Badger SA, Beattie GC, Carson J, Garstin WI (2007) Malignant neoplasms of the appendix. Int J Colorectal Dis 22(10):1239–1248

    PubMed  Google Scholar 

  113. Bucher P, Gervaz P, Ris F, Oulhaci W, Egger JF, Morel P (2005) Surgical treatment of appendiceal adenocarcinoid (goblet cell carcinoid). World J Surg 29(11):1436–1439

    PubMed  Google Scholar 

  114. Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R et al (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 87(1):31–39

    CAS  PubMed  Google Scholar 

  115. Vogelsang H, Siewert JR (2005) Endocrine tumours of the hindgut. Best Pract Res Clin Gastroenterol 19(5):739–751

    CAS  PubMed  Google Scholar 

  116. Kang H, O'Connell JB, Leonardi MJ, Maggard MA, McGory ML, Ko CY (2007) Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis 22(2):183–189

    PubMed  Google Scholar 

  117. Kimura N, Sasano N (1986) Prostate-specific acid phosphatase in carcinoid tumors. Virchows Arch A Pathol Anat Histopathol 410(3):247–251

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Sciences, University Hospital, Uppsala, SE 751 85, Sweden

    Göran Åkerström MD, PhD, Peter Stålberg MD, PhD, Olov Norlén MD, PhD & Per Hellman MD, PhD

Authors
  1. Göran Åkerström MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Stålberg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olov Norlén MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Per Hellman MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Göran Åkerström MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Suayib Yalcin

  2. Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden

    Kjell Öberg

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Åkerström, G., Stålberg, P., Norlén, O., Hellman, P. (2015). Surgical Approach in the Treatment of Neuroendocrine Tumours. In: Yalcin, S., Öberg, K. (eds) Neuroendocrine Tumours. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45215-8_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45215-8_25

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45214-1

  • Online ISBN: 978-3-662-45215-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation